A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Imiglucerase (Cerezyme)

Hydrolytic Lysosomal Glucocerebroside-specific Enzyme class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval1994-05-23
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$21.2M in CY2024 Part D spend671 claims · 76 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Imiglucerase used for?

Imiglucerase is a Hydrolytic Lysosomal Glucocerebroside-specific Enzyme medication tracked in Medicare Part D.

Is there a generic for Imiglucerase?

No. Imiglucerase is brand-only with no generic equivalents currently in market.

How much does my plan pay for Imiglucerase?

NADAC pricing data not currently available for this drug.

Is Imiglucerase on the FDA shortage list?

No. Imiglucerase is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Hydrolytic Lysosomal Glucocerebroside-specific Enzyme2 alternatives in D1
01
Taliglucerase Alfa
Brand: ELELYSO
Lowest NADAC
0Generic mfrs
$3.9MCY24 Part D spend
Compare →
02
Velaglucerase Alfa
Brand: VPRIV
Lowest NADAC
0Generic mfrs
$14.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.